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A B S T R A C T
Background: Changes in the default mode network (DMN) activity are early features of Alzheimer’s
disease (AD) and may be linked to AD-specific Ab pathology.
Methods: Cognitive profiles; DMN connectivity alterations; and cerebrospinal fluid (CSF) amyloid beta
(Ab)1–42, total tau, phosphorylated tau 181, and a-synuclein levels were studied in 21 patients with AD
and 10 controls.
Results: DMN activity is altered in AD. Posterior cingulate cortex (PCC) functional connectivity with other
parts of DMN was related to cognitive function scores. The reduction of connectivity of the dorsal PCC
with the retrosplenial cortex on the right side was closely related to decreased CSF Ab1–42 levels in
patients with AD.
Conclusions: The dorsal PCC and retrosplenial cortex may have special importance in the pathogenesis
and cognitive findings of AD.
ã 2015 Elsevier Ireland Ltd. All rights reserved.
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Alzheimer’s disease (AD) is the most common neurodegenera-
tive disease, which is characterized by distinct clinical features,
pathology, and pathogenesis. An early diagnosis of AD can be made
using well-established biomarkers and imaging markers. These
markers are expected to be the rational use of therapeutics for
halting the progression of the AD-specific pathophysiological
cascade and thus preventing Alzheimer’s dementia. Concomitant
with this idea, increasing efforts have been made to find new
markers and to improve the existing ones used for AD and other
neurodegenerative disorders.
A proposed model of the AD pathophysiological cascade
suggests that the initial detectable pathophysiological change in
AD is the accumulation of amyloid beta (Ab) in the brain (Hardy,
1992; Selkoe, 2002). Accordingly, the detection of Ab deposition on
positron emission tomography (PET) and decreased cerebrospinal* Corresponding author. Hacettepe University Faculty of Medicine, Department of
Neurology, Ankara 06100, Turkey.
E-mail address: esensaka@hacettepe.edu.tr (E. Saka).
http://dx.doi.org/10.1016/j.archger.2015.09.010
0167-4943/ã 2015 Elsevier Ireland Ltd. All rights reserved.fluid (CSF) Ab levels are expected to be the earliest signs for
diagnosing AD in vivo (Blennow, Zetterberg, & Fagan, 2012;
Sperling et al., 2011). Measures of synaptic dysfunction, such as a
regional decrease in glucose metabolism, demonstrated by
fluorodeoxyglucose (FDG) PET and altered connectivity patterns
in functional magnetic resonance imaging (fMRI) closely follow
these Ab changes. Likewise, specific alterations in resting-state
networks, in particular changes in the default mode network
(DMN), are evident in prodromal AD. On the other hand, the
elevated CSF total-tau (t-tau) and phosphorylated tau 181
(p-tau181) levels are believed to be indicators of neuronal injury.
Therefore, they occur relatively later in the development of AD
pathology (Blennow et al., 2012).
Resting-state networks are active during rest and can be either
task positive or task negative (Rektorova, 2014). DMN is a task-
negative network measured by resting-state fMRI. It is closely
related to higher cognitive functions and is largely believed to
reflect the transit of early disease-specific molecular alterations to
evident neurodegeneration in degenerative diseases such as AD
(Barkhof, Haller, & Rombouts, 2014). It has already been shown that
resting-state networks, such as DMN and the central executive
network, are altered in AD (Gour et al., 2014; Hahn et al., 2013).
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revealing similar altered patterns of functional connectivity (FC)
in patients with both sporadic and autosomal dominant AD
(ADAD). Several studies have also analyzed the validity of DMN
activity changes in diagnosing AD and reported a specificity and
sensitivity of 70–80% (Balthazar, de Campos, Franco, Damasceno, &
Cendes, 2014; Koch et al., 2012; Li et al., 2012). The disruption of
DMN has been demonstrated as a very early feature in AD; even the
asymptomatic carriers of ADAD mutations and individuals at risk
of AD, such as patients with mild cognitive impairment, elderly
carriers of ApoEe4, and cognitively normal patients with PET
demonstrating Ab deposition, experience decreases in the DMN
connectivity (Chhatwal et al., 2013; Elman et al., 2014; Jack et al.,
2013; Koch et al., 2014; Sperling et al., 2009).
The National Institute on Aging and the Alzheimer’s Association
(NIA-AA) recently established a revised diagnostic criteria for AD
dementia (McKhann et al., 2011) and recommended the use of CSF
biomarkers, such as decreased CSF Ab1–42 levels and elevated CSF
t-tau and p-tau181 levels, in addition to PET or magnetic resonance
imaging (MRI), for detecting AD, when there is a need to confirm
that the dementia syndrome is caused by AD. There are a
considerable number of studies comparing or combining different
biomarkers for diagnosing AD, although there are only a few
studies that analyze both DMN connectivity and CSF biomarkers
and their relationship in AD (Wang et al., 2013; Li et al., 2013;
Sheline et al., 2010). In the present study, we hypothesized that the
biomarkers of AD in different modalities (i.e., protein markers and
imaging markers) and the magnitude of clinical dysfunction are
related if the proposed model of the AD pathophysiological cascade
was valid. Furthermore, finding a significant correlation between
the well-established CSF biomarkers and changes in DMN activity,
particularly in the specific regions of the brain, could increase the
diagnostic utility of DMN activity studies in AD. Therefore, in the
present study, we analyzed the CSF Ab1–42, t-tau, and p-tau181
levels as well-known biomarkers of AD pathology as well as the
CSF a-synuclein levels as another marker of synaptic and/or
neuronal injury in a group of newly diagnosed patients with AD in
comparison with the controls. DMN activity and cognitive profiles
of the same subjects were also comparatively examined in relation
to these biomarkers.
2. Methods
2.1. Subjects and clinical assessment
Twenty-one patients with probable AD and 10 age-matched
healthy controls participated in the present study. Written
informed consent was obtained from all participants and/or a
family member. The study was approved by the Ankara University
Faculty of Medicine Ethical Board for Clinical Studies. The clinical
diagnosis of AD was based on the National Institute of Neurological
and Communicative Disorders and Stroke–Alzheimer’s Disease
and Related Disorders Association criteria (McKhann et al., 1984,
2011). Patients with AD were prospectively recruited from the
Neurology outpatient clinics at the Hacettepe University Hospitals
between September 2012 and June 2014. Controls were recruited
from the community. Healthy controls had no cognitive complaints
or a history of neurological disease. The mini-mental state
examination (MMSE), geriatric depression scale (GDS), and a
neuropsychological test battery, including enhanced cued recall,
semantic fluency, phonemic fluency, trail making test A and B,
reciting months backwards, and clock drawing tests (evaluated
according to a 4-point scoring system), were administered to all
subjects. The administration and scoring of these tests were as
previously described (Cangoz, Karakoc, & Selekler, 2006; Celebi,
Temucin, Elibol, & Saka, 2014; Saka, Mihci, Topcuoglu, & Balkan,2006). Clinical assessment, MRI data acquisition, and CSF
collection (only for patients with AD) were performed within a
1-week period in each subject.
2.2. CSF collection and analysis of biomarkers
CSF was collected according to new consensus-based recom-
mendations for preanalytical issues with AD and Parkinson’s
disease (PD) CSF biomarker analysis (del Campo et al., 2012). In
brief, atraumatic lumbar puncture was performed using a 22-
gauge needle in the L4–5 or L3–4 intervertebral space to remove
12 mL CSF. No serious adverse event was reported. CSF samples
were centrifuged at 2000  g for 10 min within 30 min of
collection. Samples were aliquoted into 0.5-mL polypropylene
storage tubes and stored in a 80 C freezer until analysis. All
archived samples were analyzed at the Clinical Biochemistry
Laboratory at Hacettepe University Hospitals.
CSF Ab1–42, t-tau, and p-tau181 levels were analyzed using plate-
based enzyme-linked immunosorbent assay (ELISA) (INNOTEST;
Innogenetics, Ghent, Belgium). CSF a-synuclein was measured
using ELISA (catalog no. SIG 38974; Covance, Dedham, MA)
according to the manufacturer’s instructions. CSF hemoglobin
levels were also determined to evaluate blood contamination and
to control the possible confounding effect of hemolysis on the
CSF a-synuclein level. CSF hemoglobin was analyzed using the
ELISA method with reagents obtained from Bethyl Laboratories
according to the manufacturer’s instructions. CSF protein
concentrations were determined using a colorimetric method by
Beckman Coulter analyzers.
2.3. Imaging methods
2.3.1. Data acquisition and preprocessing
All imaging data of the brain were obtained on a 3T MR scanner
(Magnetom, Trio TIM system; Siemens, Germany) equipped with
an 8-channel phased-array head coil. A T2*-weighted gradient-
echo spiral pulse sequence (repetition time [TR] 2000 ms; time to
echo [TE], 30 ms; flip angle, 80) was used for the resting-state
functional scans. It comprised 150 dynamic series that required
5 min. The field of view (FOV) was 230  230 mm2, and the matrix
size was 64  64, giving an in-plane spatial resolution of 3.6 mm.
The subjects kept their eyes closed and remained still without
concentrating on anything specific. For anatomical data, all
subjects also underwent structural T1-weighted three-dimension-
al (3D) high-resolution images with 0.9-mm isotropic voxels
[magnetization-prepared rapid gradient-echo-(MPRAGE)] (TR/TE:
1900/3.4 ms; FA: 90; FOV: 256 mm; matrix: 224  256; distance
factor: 50%).
Data were preprocessed using SPM8 software (Statistical
Parametric Mapping SPM Software, 2015). Motion correction
using least-squares minimization without higher-order correc-
tions for spin history and normalization (Friston et al., 1995) of
both functional and structural 3D T1-weighted MPRAGE data to the
Montreal Neurological Institute (MNI) template were performed.
Images were then resampled every 2-mm isotropic voxel size using
sinc interpolation and smoothed with a 4-mm full width at half
maximum (FWHM) Gaussian kernel to decrease the spatial noise.
Resampling and smoothing were done in three dimensions
yielding a 2-mm3 resolution and effective spatial smoothness
(FWHM) of 7.2  7.1 8.4 mm. Normalized data of each subject
were used as input for MELODIC independent component analysis
(Beckmann & Smith, 2004) for identifying and removing noise
components. Temporal filtering was applied using both high-pass
(Gaussian-weighted least-squares straight line fitting, with
sigma = 100.0 s) and low-pass filters (Gaussian low-pass temporal
filtering: half-width at half-maximum, 2.8 s).
Table 1






Age (yrs) 66.4  1.9 66.6  2.3 0.852
Education (yrs) 9.3  1.3 10.3  1.3 0.917
Gender (F/M) 8/13 8/2 0.054
Disease duration (yrs) 2.8  0.3 – N/A
MMSE
(range)
18.1  1.4 (11-23) 27.5  0.7 (24-30) 0.002
ECR 16.2  2.9 46.1  0.7 0.002
Semantic fluency 8.4  0.7 15.7  1.2 0.002
Verbal fluency 5.7  1.0 9.7  1.5 0.028
Trail making A 165.6  25.3 66.8  9.6 0.024
Trail making B 293.4  16.3 144.0  26.0 0.002
Reciting months backwards 167.8  28.6 80.9  37.1 0.024
Clock drawing test 2.2  0.4 3.8  0.1 0.024
GDS 4.4  1.1 1.5  0.5 0.025
AD, Alzheimer’s disease; MMSE, mini-mental state examination; ECR, enhanced
cued recall test; GDS, geriatric depression scale; SEM, standard error of mean.
* Adjusted p values according to the False Discovery Rate (FDR); N/A, statistical
analysis is not available.
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analysis of FC in individuals and analysis of the seed-voxel group
for building a composite map for the entire group of similar
subjects in Fig. 2. All of the presented data, except the data in Fig. 2,
are the results of individual seed-based connectivity analysis.
2.3.2. FC analysis (individual seed-based connectivity)
For individual seed-based connectivity, FMRIB’s Software
Library (www.fmrib.ox.ac.uk/fsl) (FSL, 2015) was used to examine
functional coupling respectively between the posterior cingulate
cortex (PCC), left dorsal PCC, right dorsal PCC, left ventral PCC, right
ventral PCC (Supplementary Table 1), and seven other regions of
interest (ROI) (Supplementary Table 2) located in DMN regions
during the resting state. Each subject’s time series was trans-
formed into MNI space using 12 of freedom linear affine
transformation implemented in FLIRT (voxel size = 1 1 1 mm)
to obtain the time series for each seed, for each subject. ROI was
defined as spheres with a 6-mm radius. To form a sphere mask
around a voxel of interest, the fslmaths commands were used. The
mean time series was extracted from a normalized and trans-
formed fMRI for all of the sphere-masked voxels using the
fslmeants command. The FEAT toolbox (FEAT, 2015) was used with
the seed time series file that was just created to perform multiple
regression analyses (Di et al., 2008). To extract the unique variance
that the time series for each seed mask reflects, time series for each
seed were orthogonalized with respect to each other using the
Gram–Schmidt process. Individual subject-level maps of all
positively and negatively predicted voxels for each regressor were
created by this analysis, and Z-score values were calculated for
each subject (Margulies et al., 2007).
2.3.3. FC analysis (seed-voxel group analysis)
Using the CONN toolbox in MATLAB R2008a (www.nitrc.org/
projects/conn), principal components associated with segmented
white matter and CSF for each subject were identified, and white
matter, CSF, and realignment parameters were entered as
confounders in a first-level analysis. The data were band-pass
filtered to 0.008–0.09 Hz. For a group analysis, seed-voxel analysis
was then used, and connectivity patterns were separately
specified for five 6-mm spherical clusters; five seed ROI located
in PCC, the left dorsal PCC, the right dorsal PCC, the left ventral
PCC, and the right ventral PCC. Using the specified five seed
ROI, temporal correlations were computed between these
seeds and all other voxels in the brain. Seed-to-voxel results
were reported as significant at a voxel-wise threshold
level of p < 0.001 uncorrected and a cluster-level threshold of
p < 0.05 corrected for the false discovery rate (FDR). The t-test
and Fisher’s Z-transformed correlations were used to compute
differences in FC between the patients with AD and healthy
controls.
2.4. Statistical analysis
Mean  standard error of the mean values are used to describe
the quantitative variables. Frequencies and percentages are given
for nominal data. Normality assumption was checked using the
Shapiro–Wilk test. Independent samples t test and Mann–Whitney
U test were used to compare the groups in terms of quantitative
variables. The sex distribution among the study groups was
analyzed using Fisher’s exact test. An exploratory factor analysis
(using principal component analysis for factor extraction) was
applied to combine several quantitative variables into a single
factor to reduce high-dimensional data. Accordingly, PCC (the
connectivity of PCC with the other nodes of the DMN), ventral PCC
(the connectivity of the right and left ventral PCC with the other
nodes of DMN), dorsal PCC (the connectivity of the right and leftdorsal PCC with the other nodes of the DMN), memory (enhanced
cued recall and semantic fluency), and executive function (trial
making B, reciting months backwards, and verbal fluency) factors
were built. For all extracted factors, explained variances were more
than 50% with a single factor. The nonparametric Spearman
correlation analysis (without applying any covariate adjustment)
was then used to analyze the relationship between both the
quantitative variables and extracted factors. The FDR control was
applied for all analyses to correct for multiple comparisons
(Benjamini & Hochberg, 1995). IBM-SPSS version 21.0 (IBM Corp.,
Armonk, NY) and R package “p.adjust” (R Core Team, 2013) version
3.0.2 (The R Foundation for Statistical Computing) were used, and
the statistical significance was set at p < 0.05.
3. Results
3.1. Demographics and cognitive profile
The demographics and cognitive features of subjects are
summarized in Table 1. Patients with AD and controls were
matched for age, education, and sex. In patients with AD, disease
severity was mild to moderate, with a mean MMSE score of
18.1 1.4, whereas the mean MMSE score of the control group was
27.5  0.7. The performance of patients with AD was lower than
that of the controls in all of the neuropsychological tests
administered (all p values <0.05). The GDS score was higher in
patients with AD than controls (p = 0.025).
3.2. CSF biomarkers
CSF Ab1–42, t-tau, p-tau181, and a-synuclein levels and ratio of
a-synuclein to total protein in patients with AD are presented in
Table 2. These values were compared with another group of
control subjects (n = 24) who underwent diagnostic lumbar
puncture for headache or peripheral nervous system disorders.
None of them had neurodegenerative disease. As expected,
patients with AD had a lower CSF Ab1–42 and higher CSF t-tau
and p-tau181 levels than controls (p < 0.05). Patients with AD had
higher CSF a-synuclein levels than controls (2035.2  266.5 vs.
1425.9  182.5 pg/mL, respectively; p < 0.05) as well as a higher
ratio of a-synuclein to total protein (51.8  6.5 vs. 35.5  4.7;
p < 0.05). This ratio correlated with the level of p-tau181 in patients
with AD.
Table 2
CSF biomarkers, results of the subjects with AD and controls.
AD (n = 21)
Mean  SEM
Control (n = 24)
Mean  SEM
p Value
Ab1–42 (pg/ml) 772.3  64.5 1089.2  44.8 <0.0001
t-tau (pg/ml) 681.2  60.5 278.6  31.4 <0.0001
p-tau181, (pg/ml) 90.6  6.5 41.6  3.9 <0.0001
a-Synuclein (pg/ml) 2035.2  266.5 1425.9  182.5 0.047
a-Synuclein to total protein, ratio 51.8  6.5 35.5  4.7 0.047
AD, Alzheimer’s disease; SEM, standard error of mean.
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The cognitive test results were not related to any of the
AD-related CSF biomarkers (Ab1–42, t-tau, and p-tau181) or
a-synuclein levels.
3.4. Comparison of DMN FC across groups
We used individual seed-based connectivity analysis for the
comparison of DMN FC across groups. A DMN connectivity map
derived from PCC (PCC as a whole and dorsal PCC and ventral PCC
separately on both sides) showed decreased FC with the medial
prefrontal cortex, medial temporal lobes, inferior parietal lobules,
and retrosplenial cortices in patients with AD relative to age-
matched controls (Fig. 1; p < 0.05). We also performed seed-voxel
group analysis for the visual comparison of AD and healthy control
groups (Fig. 2).
3.5. Correlation of DMN integrity changes with cognitive functions
Data derived from individual seed-based connectivity analyses
were used for correlation studies. Patients with AD and healthy
controls were analyzed as a whole. To avoid multiple compar-
isons, the connectivity of PCC with the other nodes of DMN as a
single unit (the PCC factor, which was extracted using factor
analysis) was analyzed. We also classified neuropsychological test
scores into four cognitive domains: memory (enhanced cued
recall and semantic fluency), visuospatial (clock drawing),
attention (trial making A), and executive functions (trial making
B, reciting months backwards, and verbal fluency) and asked
whether the PCC factor was related to the cognitive performance
of study subjects. This analysis showed that the PCC factor
was related to the MMSE score (r = 0.546, p = 0.001), attention
(r = 0.392, p = 0.029), executive function factor (r = 0.429,
p = 0.016), GDS score (r = 0.522, p = 0.003), and more prominently
with memory factor (r = 0.647, p = 0.0001) (Table 3).
The results of further correlation analyses of PCC connectivity
with the other nodes of DMN separately and individual cognitive
test scores are summarized in Table 4. This analysis demonstrated
the presence of significant correlations between individual
cognitive test scores and connectivity of their functionally related
DMN nodes with PCC.
3.6. Correlation of DMN integrity changes with CSF biomarkers
Data derived from individual seed-based connectivity analyses
were used for correlation studies. Because CSF biomarkers were
not studied in healthy controls, this analysis was conducted only in
patients with AD. We first analyzed whether PCC connectivity as a
whole (PCC factor) was related to any of the CSF markers of AD and
found that CSF Ab1–42 levels tended to correlate with the level of
connectivity of PCC, although this did not reach statistical
significance (r = 0.421, p = 0.058).Next, we sought the level of connectivity of the dorsal and
ventral PCC with each DMN node individually. This analysis
showed that among other DMN nodes, the connectivity of the
dorsal PCC with the retrosplenial cortex on the right side was
significantly related to CSF Ab1–42 levels (r = 0.499, p = 0.021). This
finding shows that the amount of decrease of Ab1–42 in CSF is
related to a decrease in dorsal PCC and retrosplenial cortex
connectivity.
4. Discussion
In the present study, we showed that, in a resting state, the
connectivity of PCC with the medial prefrontal cortex, medial
temporal lobes, inferior parietal lobules, and retrosplenial cortices
is decreased in patients with newly diagnosed mild to moderate
AD. As expected, these patients had a lower CSF Ab1–42 and higher
CSF t-tau and p-tau181 levels than controls. We additionally found
that CSF a-synuclein levels were increased in these patients. The
comparative analysis of all these biological and imaging param-
eters together with cognitive profiling depicted some expected as
well as novel findings. When patients with AD and healthy controls
were analyzed as a whole, the scores of cognitive functions, such as
attention, executive functions, and more prominently memory
domains, were related to the magnitude of PCC connectivity with
other parts of DMN. Moreover, as a novel finding, in DMN,
decreased connectivity of the dorsal PCC with the retrosplenial
cortex was found to be closely related to decreased CSF Ab1–42
levels in patients with AD.
DMN includes medial temporal, frontal, and parietal cortical
areas. It isactivewhen attentionisnot focusedbut deactivatesduring
task-related activities (Buckner, Andrews-Hanna, & Schacter, 2008).
In studies of AD, changes in DMN activity particularly involved FC
between PCC and hippocampus/medial temporal lobes (Greicius,
Srivastava, Reiss, & Menon, 2004; Wang et al., 2013). When studying
PCC connectivity, we also analyzed dorsal and ventral PCC separately
because FC of the dorsal and ventral PCC may differ in the resting
state and during cognitive tasks. For example, similar to the ventral
PCC, the dorsal PCC has strong connectivity within DMN; however,
unlike the ventral PCC, it also has connectivity to a wide range of
other intrinsic connectivity networks, including frontal and parietal
regions involved in cognitive control (Leech & Sharp, 2014). We
found here that FC of PCC (ventral, dorsal, or total) with the other
parts of DMN is altered in patients with AD. We further showed that
the strengthof PCC FC is lower insubjects with lowercognitive scores
and higher in subjects with higher cognitive function. This finding is
in accordance with previous studies that showed the alteration of
PCC FC to be proportional to the severity of the disease (Chhatwal
et al., 2013).
The widely accepted and largely proved pathophysiological
cascade of AD suggests that altered Ab production and its deposition
is a very early step and leads to other AD-related neuronal and circuit
changes (Hardy, 1992; Sperling et al., 2011). Preferentially, Ab-
deposited areas include the nodes of DMN such as PCC, retrosplenial
cortex, precuneus, and parietal and temporal lobes (Wang et al.,
2013; Buckner et al., 2005). Several studies have reported an
association between CSF biomarkers and DMN connectivity changes
(Wang et al., 2013; Li et al., 2013; Sheline et al., 2010). Among them,
Wang et al. (2013) found associations of decreased CSF Ab1–42 levels
and increasedCSFp-taulevels with decreasesofFC ofPCCand medial
temporal lobes in a large sample of cognitively normal older
individuals. Li et al. (2013) showed that the ratio of Ab42 to p-
tau181 correlated with FC within DMN in the left precuneus in AD.
Based on this background, we expected changes in DMN in patients
with AD to be related to Ab deposition and CSF Ab levels in our
subjects. Indeed,we found thatCSFAb levels were relatedto FCof the
dorsal PCC with the retrosplenial cortex on the right side. In other
Fig. 1. Box-and-whisker plots of the functional connectivity values between (A) the posterior cingulate cortex (PCC) and the other default mode network (DMN) regions (B)
right ventral PCC and the other DMN regions (C) Left ventral PCC and other DMN regions (D) right dorsal PCC and other DMN regions (E) left dorsal PCC and other DMN regions.
Figure shows reduced connectivity of the PCC and ventral/dorsal PCC with the medial prefrontal cortex (MPFC), medial temporal lobes (MTL), inferior parietal lobules (IPL),
and retrosplenial cortices (RSC) in Alzheimer’s disease (AD) patients. *p < 0.05, according to the False Discovery Rate (FDR) adjustment. In the Box-and-whisker plot, the box
represents the values from the lower to upper quartile (the interquartile range) and the middle line represents the median of the functional connectivity values.
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Fig. 2. Functional connectivity between the PCC and all other brain regions in the control group (A), in AD group (B). Figure shows reduced functional connectivity with
medial prefrontal cortex, medial temporal lobes, inferior parietal lobules and retrosplenial cortices in AD patients relative to age-matched controls (two sided FDR *p < 0.05,
seed-level corrected *p < 0.05).
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Table 3
Correlation of the default mode network (DMN) functional connectivity (FC) values with the cognitive test scores in study subjects.
MMSE Memory factor Visuo-spatial function Attention Executive function factor GDS
r p r p r p r p r p r p
PCC factor 0.55 0.001 0.65 <0.0001 0.32 NS 0.39 0.029 0.43 0.016 0.52 0.003
Ventral PCC factor 0.64 <0.0001 0.69 <0.0001 0.42 0.02 0.38 0.035 0.50 0.004 0.45 0.011
Dorsal PCC factor 0.58 0.001 0.66 <0.0001 0.37 0.041 0.35 NS 0.48 0.006 044 0.014
PCC-R/L MTL 0.52 0.002 0.52 0.003 0.42 0.018 0.24 NS 0.30 NS 0.48 0.007
R/L Dorsal PCC-R/L MTL 0.51 0.003 0.53 0.002 0.36 0.045 0.26 NS 0.34 NS 0.39 0.029
R/L Ventral PCC-R/L MTL 0.51 0.003 0.55 0.001 0.36 NS 0.22 NS 0.33 NS 0.40 0.026
MMSE, mini-mental state examination; GDS, geriatric depression scale; PCC, posterior cingulate cortex; R, right; L, left; MTL, medial temporal lobe; NS, non-significant; PCC
factor, the connectivity of PCC with the other nodes of DMN as a single factor which is extracted by using factor analysis; Ventral PCC factor, the connectivity of R and L ventral
PCC with the other nodes of DMN as a single factor which is extracted by using factor analysis; Dorsal PCC factor, the connectivity of R and L dorsal PCC with the other nodes of
DMN as a single factor which is extracted by using factor analysis; Memory factor, a single factor of enhanced cued recall and semantic fluency; Executive function factor, a
single factor of trial making B, reciting months backwards, verbal fluency.
Table 4
Correlation analysis of the PCC functional connectivity with the other DMN nodes and the neuropsychological test scores in the study groups.
PCC-MPFC PCC-RMTL PCC-LMTL PCC- RIPL PCC-LIPL PCC-RRSC PCC-LRSC
r p r p r p r p r p r p r p
MMSE 0.38 0.033 0.44 0.013 0.65 <0.0001 0.44 0.013 0.24 NS 0.44 0.012 0.33 NS
ECR 0.53 0.002 0.63 <0.0001 0.69 <0.0001 0.60 <0.0001 0.40 0.025 0.44 0.015 0.32 NS
Semantic fluency 0.29 NS 0.24 NS 0.46 0.010 0.53 0.002 0.35 NS 0.48 0.006 0.50 0.004
Verbal fluency 0.11 NS 0.002 NS 0.25 NS 0.38 0.038 0.07 NS 0.33 NS 0.11 NS
Trail making A 0.13 NS 0.08 NS 0.47 0.007 0.36 0.049 0.07 NS 0.49 0.006 0.23 NS
Trail making B 0.24 NS 0.43 0.015 0.62 <0.0001 0.58 0.001 0.17 NS 0.45 0.011 0.22 NS
Reciting months backwards 0.11 NS 0.12 NS 0.40 0.026 0.31 NS 0.03 NS 0.39 0.032 0.32 NS
Clock drawing 0.20 NS 0.33 NS 0.52 0.003 0.24 NS 0.15 NS 0.28 NS 0.10 NS
GDS 0.47 0.008 0.40 0.027 0.54 0.002 0.34 NS 0.27 NS 0.16 NS 0.28 NS
MMSE, mini-mental state examination; ECR, enhanced cued recall; GDS, geriatric depression scale; PCC, posterior cingulate cortex; R, right; L, left; MTL, medial temporal lobe;
IPL, inferior parietal lobul; MPFC, medial prefrontal cortex; RSC, retrosplenial cortex.
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the retrosplenial cortex was lower. This finding is novel but not
unexpected. Previous FDG PET studies showed decreased glucose
metabolism in the veryearlystages of AD in PCC and the retrosplenial
cortex (Buckner et al., 2005; Frings, Spehl, Weber, Hull, & Meyer,
2013). It was also shown to be associated with increased amyloid
deposition and/or atrophy in these regions and the brain regions
anatomically and functionally connected to them (Buckner et al.,
2005; Desgranges et al., 2002; Frings et al., 2013). The retrosplenial
cortex functions in spatial navigation and in acquiring new
information,particularlyautobiographicalmemory(Vann,Aggleton,
& Maguire, 2009). It has connections with the hippocampal
formation, parahippocampal region, and anterior and lateral dorsal
thalamic nuclei as well as with PCC. Owing to those findings and
others, the retrosplenial cortex in addition to PCC is believed to play a
major role in cognitive deficits associated with AD (Pengas et al.,
2012). The involvement of dorsal but not the ventral PCC may be
because of the more deliberate use of the dorsal PCC, as it is believed
to link networks that are functionally distinct but need to be
coordinated for efficient cognitive processing (Leech & Sharp, 2014).
Consistent with this idea, Sperling et al. found that increased Ab
deposition is associated with higher DMN activity during a memory
task (Sperling et al., 2009).
Additionally, we analyzed CSF a-synuclein levels as a protein
marker of synaptic degeneration not specific to AD. In fact,
a-synuclein is being studied as a biomarker of PD and other
a-synucleinopathies. It is decreased in PD, multiple system
atrophy, and Lewy body dementia (Mollenhauer et al., 2008;
Mondello et al., 2014). However, a-synuclein is reported to
be elevated in Creutzfeldt–Jacob disease (Kasai et al., 2014;
Mollenhauer et al., 2008), traumatic brain injury (Mondello, Buki,Italiano, & Jeromin, 2013), and AD (Slaets et al., 2014). Our finding
of increased CSF a-synuclein levels in patients with AD is in
accordance with those studies. Furthermore, we found that the
a-synuclein levels positively correlated with increased p-tau181
in patients with AD. These findings further support the view
that the decreased CSF a-synuclein levels can be a marker of
synucleinopathies; however, an increase in CSF a-synuclein levels
may indicate neurodegeneration irrespective of the underlying
neuropathology.
This study has several limitations. The control group was small
and mostly composed of women. For ethical reasons, we could not
obtain CSF samples from healthy controls; hence, all the correlative
data between changes in DMN and CSF biomarker levels were
derived from patients with AD. Further studies in a larger sample of
both control and patient groups covering prodromal to advanced
stages of AD are required. These studies may allow a reliable
assessment of the diagnostic power of changes in DMN activity in
diagnosing AD compared with CSF biomarkers or other validated
biomarkers.
5. Conclusions
The data show that DMN activity changes in AD and is closely
related to cognitive functions and Ab pathology. The findings
further indicate that the dorsal PCC and retrosplenial cortices may
have special importance in the pathogenesis and cognitive findings
of AD.
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